Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announced that Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation of Allergy Therapeutics, will present at the Cowen 42nd Annual Health Care Conference taking place from 07-09 March 2022.
The presentation will review data supporting the upcoming clinical trials for the Group’s lead pipeline candidates including Grass MATA MPL, which is expected to enter Phase III development in Q3 2022, and VLP Peanut, which is on track to enter the clinic in the Phase I PROTECT trial later this year.
A replay of the presentation will be made available under the ‘Investors’ section on Allergy Therapeutics’ website at www.allergytherapeutics.com/investors/results-reports-and-presentations/.
